Characteristics of patients with FLT3 mutations.
N | 18 |
Median age at diagnosis | 13 (6–19) |
Gender (N) F:M | 11:7 |
Prognostic factors (%) | |
Primary refractory | 5 (27.8) |
High WBC counta) | 4 (22.2) |
Secondary AML | 2 (11.1) |
FAB (N, %) | |
M1 | 7 (38.9) |
M2 | 4 (22.2) |
M4 | 6 (33.3) |
M5 | 1 (5.5) |
Cytogenetic/molecular (N, %) | |
Normal | 9 (50) |
0 | |
1 (5.5) | |
0 | |
3 (16.7) | |
1 (5.5) | |
Induction chemotherapy (N, %) | |
BH-AC-basedb) | 14 (77.7) |
Cytarabine-basedc) | 4 (22.2) |
HSCT (N, %) | 17 (94.4) |
MUD | 9 (52.9) |
MRD | 5 (27.8) |
Haploidentical | 3 (16.7) |
a)WBC count of >100×109/L at diagnosis; b)enocitabine, idarubicin, intrathecal cytarabine; c)cytarabine, idarubicin, mitoxantrone.
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; DOD, died of disease; FAB, French-American-British classification; HSCT, hematopoietic stem cell transplant; MRD, matched related donor; MUD, matched unrelated donor; N, number; TRM, treatment-related mortality.